Mucormycosis in the Hand

Jerome, J. Terrence Jose; Thirumagal, K

doi:10.2106/jbjs.cc.22.00510

Cited by 1 publication

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment of burn patients with superinfection includes aggressive debridement guided by frozen section in association with antifungal therapy [52]. Flap reconstruction following debridement and treatment with systemic antifungal therapy has been used with success [82]. Kaushal et al ] were able to achieve better than normal outcomes in diabetic patients with head and neck MCR by combining aggressive serial debridement, AMB, followed by posaconazole in some cases, with close monitoring of blood glucose for diabetic patients, aggressive electrolyte repletion, and serial irrigation.…”

Section: Treatment Of Mucormycosismentioning

confidence: 99%

See 1 more Smart Citation

Mucormycosis: update on clinical presentation, diagnosis, and treatment

Dailey Garnes,

Kontoyiannis

2023

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Purpose of review Mucormycosis (MCR) is a common opportunistic mold infection, and Mucorales were recently designated by WHO as priority pathogens. The interest in this infection has risen significantly since the major outbreak of MCR in the context of the COVID-19 pandemic, particularly in India. Herein, we summarize recently (last 24 months) published information regarding clinical aspects of MCR. Recent findings The disease remains protean in its clinical presentation, difficult to diagnose, and challenging to treat. In 2021, cases of COVID-19-associated mucormycosis (CAM) exploded in India during COVID-19 and manifested primarily as sino-orbital or sino-cerebral disease. Its classic risk factors included the triad of COVID-19, uncontrolled diabetes mellitus and use of corticosteroids. Despite difficulties in the timely diagnosis of MCR, significant progress has been made with the use of molecular techniques in blood to assist with earlier diagnosis, which can facilitate earlier appropriate therapy and improve outcomes. In addition, advances have been made in the use of imaging to stage the disease, determining what types of multimodal therapy are required depending on staging, and tissue-based identification of Mucorales. Summary Although the outlook for MCR has improved, effective new antifungals, risk stratification, and the optimal multimodality approaches remain an unmet need.

show abstract

Section: Treatment Of Mucormycosismentioning

confidence: 99%

Section: Treatment Of Mucormycosismentioning

confidence: 99%